Summary Statement: ADARC Program Project on HIV/SIV Vaccine Development

PAGE 34

1 P01 AI43042-01 9 SEP
Ho, Dav id D. 4'f 4C CCSf
while the construction of an env protein that stimulates antibodies to
critical epitopes is a worthwhile objective, it has already been pursued by
many other investigators. In addition, it is completely unclear which of the
participating investigators would be doing what, thereby making it nearly
impossible to judge the ability to make the necessary constructions.;
RESOURCES AND ENVIRONMENT: The facilities at both ADARC nd PHRI, n terms of
both space and equipment, are more than adequate to perfor roposed
experiments. Most laboratories (Project 1) are located on two floors of one
facility and a closely integrated primate research facility. The general
quality of the facilities is high, and both institutions are well positioned
to conduct hjgh quality, interactive research.
The full commitment of the ADARC towards AIDS research is unquestionable, and
collaboration between the investigators of all projects andcores is
excellent.
PROGRAM ADMINISTRATION: The leadership and research experience of the
Principle Investigator, Dr. D. Ho and his team are outstanding. Dr. Ho is
known worldwide for his work on HIV. The team that he has assembled at the
Aaron Diamond AIDS Research Center including Drs. Moore, Connor, Nixon, and
Marx, have also contributed greatly to our understanding of HIV. The staff,
for the most part, have the necessary experience to conduct the work.
OVERALL IRG ACTION: Based upon the evaluation by the IRG of the scientific
and technical merit of the projects and cores recommended for support, and the
interactions in the resulting overall program consisting of Projects 1, 2, and
3, and Cores B, and C, this application is, scored in the good range range
with a numerical value of 330.
PROJECT j: Live, Attenuated SIV Vaccine and Correlates of Protection
Critique: The comments below represent essentially unedited comments from the
reviewers of this application. They are included to indicate the range of
comments made during the discussion, and may not reflect the final thinking of
the committee. The RESUME and OVERALL CRITIQUE sections above summarize the
final opinion of the committee after the discussion.
REVIEHER A: This 5-year project is planned to further analyze a previous
study and perform a second study using 14 macaques to prospectively evaluateI
SIV-specific CTL and other cellular immune responses. It is very likely that
many of these studies are well underway or have already been finished based on
data given in the application or at meetings. In addition, similar 89.6 SHIV
re-challenge and mu nge o pro ec e - f es
have b ne in other research laboratories although the SIV-GFP iso te was
used. It is very surprising that despite the collection of LN for viral
RNA levels and cytokine expression, very little is to be done with them.
says are performed on PBMConl-. -

/ Continued